ArticleInternational journal of clinical and experimental medicine2015
Effect of APE1 and XRCC1 gene polymorphism on susceptibility to hepatocellular carcinoma and sensitivity to cisplatin.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- The association of six non-synonymous variants in three DNA repair genes with hepatocellular carcinoma risk: a meta-analysis.Journal of cellular and molecular medicine · 2016Pooled it
- The critical role of circular RNAs in drug resistance in gastrointestinal cancers.Medical oncology (Northwood, London, England) · 2023Review
- Enhanced DNA Repair Pathway is Associated with Cell Proliferation and Worse Survival in Hepatocellular Carcinoma (HCC).Cancers · 2021Article
- Review
- Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity.Cancers · 2020Review
- Architecture of The Human Ape1 Interactome Defines Novel Cancers Signatures.Scientific reports · 2020Article
- Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma.Cancer drug resistance (Alhambra, Calif.) · 2019Review
- Associations between three XRCC1 polymorphisms and hepatocellular carcinoma risk: A meta-analysis of case-control studies.PloS one · 2018Article
- Role of GSTP1 Ile105Val and XRCC1 Arg194Trp, Arg280His and Arg399Gln gene polymorphisms in the clinical outcome of advanced non-small cell lung cancer.International journal of clinical and experimental pathology · 2015Article
- Association of XRCC1 p. Arg194Trp gene polymorphism with the risk of hepatocellular carcinoma in HCV Egyptian population: A pilot case-control study.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe relationship between APE1 and XRCC1 gene polymorphism and the susceptibility to hepatocellular carcinoma (HCC) was discussed, and the effect of APE1 and XRCC1 gene polymorphism on the sensitivity of HCC to cisplatin was investigated.
methodFrom January 2010 to August 2014, 118 HCC patients were admitted to our hospital. 120 patients treated for non-tumor diseases during this period were recruited as controls. PCR-RFLP analyses were performed to determine the association between APE1 Asp148Glu and XRCC1 Arg194Trp polymorphism, risk of HCC, and sensitivity to cisplatin.
resultsThe risk of HCC in patients with Glu/Glu genotype of APE1 gene was increased by 4.510 times (95% CI: 1.235~16.472, P<0.05). Compared with Asp/Asp, the risk of cisplatin resistance in patients with Glu/Glu genotype was increased by 10.500 times (95% CI: 1.800~61.241). Compared Arg/Arg genotype, the risk of cisplatin resistance in patients with Arp/Trp genotype of XRCC1 gene was increased by 6.701 times (95% CI: 1.464~30.732, P<0.05).
conclusionAPE1 Asp148Glu polymorphism is associated with the susceptibility to HCC. APE1 Asp148Glu and XRCC1 Arg194Trp polymorphism plays a part in the cisplatin resistance of HCC cells.
Indexed as
Identifiers
26309678PMC4538105W1174667314What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.